Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in:

01.10.2014 | original article

Biological pathways involved in the development of inflammatory bowel disease

verfasst von: Dr. Mateja Zemljic, PhD, Prof. Bozena Pejkovic, Prof. Ivan Krajnc, Docent Saska Lipovsek

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 19-20/2014

Einloggen, um Zugang zu erhalten

Summary

Apoptosis, autophagy and necrosis are three distinct functional types of the mammalian cell death network. All of them are characterized by a number of cell’s morphological changes. The inappropriate induction of cell death is involved in the pathogenesis of a number of diseases.
Pathogenesis of inflammatory bowel diseases (ulcerative colitis, Crohn’s disease) includes an abnormal immunological response to disturbed intestinal microflora. One of the most important reason in pathogenesis of chronic inflammatory disease and subsequent multiple organ pathology is a barrier function of the gut, regulating cellular viability. Recent findings have begun to explain the mechanisms by which intestinal epithelial cells are able to survive in such an environment and how loss of normal regulatory processes may lead to inflammatory bowel disease (IBD).
This review focuses on the regulation of biological pathways in development and homeostasis in IBD. Better understanding of the physiological functions of biological pathways and their influence on inflammation, immunity, and barrier function will simplify our expertice of homeostasis in the gastrointestinal tract and in upgrading diagnosis and treatment.
Vorheriger Artikel Daytime sleepiness in patients with obstructive sleep apnea and severe obesity: prevalence, predictors, and therapy
Nächster Artikel Comparability and quality of IgE-based in vitro allergy diagnosis: 25 years of external quality assessment
Literatur
1.
Ayabe T, Satchell DP, Wilson CL, et al. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol. 2000;1(2):113–8.PubMed
2.
Cash HL, Whitham CV, Behrendt CL, Hooper LV. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science. 2006;313(5790):1126–30.PubMedCentralPubMed
3.
Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124(4):837–48.PubMed
4.
5.
Hill DA, Artis D. Intestinal bacteria and the regulation of immune cell homeostasis. Annu Rev Immunol. 2010;28:623–67.PubMed
6.
Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol. 2004;4(6):478–85.PubMed
7.
McCormick BA, Parkos CA, Colgan SP, Carnes DK, Madara JL. Apical secretion of a pathogen-elicited epithelial chemoattractant activity in response to surface colonization of intestinal epithelia by Salmonella typhimurium. J Immunol. 1998;160(1):455–66.PubMed
8.
Kagnoff MF. Microbial-epithelial cell crosstalk during inflammation: the host response. Ann N Y Acad Sci. 2006;1072:313–20.PubMed
9.
10.
Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13(4):481–9.PubMed
11.
Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91(4):854–62.PubMed
12.
Jess T, Riis L, Jespersgaard C, et al. Disease concordance, zygosity, and NOD2/CARD15 status: follow-up of a population-based cohort of Danish twins with inflammatory bowel disease. Am J Gastroenterol. 2005;100(11):2486–92.PubMed
13.
Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307–17.PubMedCentralPubMed
14.
Sartor RB. Intestinal microflora in human and experimental inflammatory bowel disease. Curr Opin Gastroenterol. 2001;17(4):324–30.PubMed
15.
Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol. 1997;92(Suppl. 12):5S–11S.PubMed
16.
Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347(6):417–29.PubMed
17.
Farrell RJ, LaMont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31(1):41–62.PubMed
18.
Shanahan F. Host-flora interactions in inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(Suppl. 1):S16–24.
19.
Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122(1):44–54.PubMed
20.
Neut C, Bulois P, Desreumaux P, et al. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn’s disease. Am J Gastroenterol. 2002;97(4):939–46.PubMed
21.
Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn’s disease. Gastroenterology. 1998;115(6):1405–13.PubMed
22.
Seksik P, Sokol H, Lepage P, et al. Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24(Suppl. 3):11–8.PubMed
23.
24.
Barnich N, Darfeuille-Michaud A. Role of bacteria in the etiopathogenesis of inflammatory bowel disease. World J Gastroenterol. 2007;13(42):5571–6.PubMedCentralPubMed
25.
Gersemann M, Stange EF, Wehkamp J. From intestinal stem cells to inflammatory bowel diseases. World J Gastroenterol. 2011;17(27):3198–203.PubMedCentralPubMed
26.
Garret WS, Gordon JI, Glimcher LH. Homeostasis and inflamation in the intestine. Cell. 2010;140(6):859–70.
27.
Cadwell K, Stappenbeck TS, Virgin HW. Role of autophagy and autophagy genes in inflammatory bowel disease. Curr Top Microbiol Immunol. 2009;335:141–67.PubMed
28.
Deretic V, Delgado M, Vergne I, et al. Autophagy in immunity against mycobacterium tuberculosis: a model system to dissect immunological roles of autophagy. Curr Top Microbiol Immunol. 2009;335:169–88.PubMedCentralPubMed
29.
Deretic V. Autophagy in innate and adaptive immunity. Trends Immunol. 2005;26(10):523–8.PubMed
30.
Levine B, Deretic V. Unveiling the roles of autophagy in innate and adaptive immunity. Nat Rev Immunol. 2007;7(10):767–77.PubMed
31.
Schmid D, Munz C. Innate and adaptive immunity through autophagy. Immunity. 2007;27(1):11–21.PubMed
32.
Andrade RM, Wessendarp M, Gubbels MJ, Striepen B, Subauste CS. CD40 induces macrophage anti-Toxoplasma gondii activity by triggering autophagy-dependent fusion of pathogen-containing vacuoles and lysosomes. J Clin Invest. 2006;116(9):2366–77.PubMedCentralPubMed
33.
Birmingham CL, Smith AC, Bakowski MA, Yoshimori T, Brumell JH. Autophagy controls Salmonella infection in response to damage to the Salmonella-containing vacuole. J Biol Chem. 2006;281(16):11374–83.PubMed
34.
Checroun C, Wehrly TD, Fischer ER, Hayes SF, Celli J. Autophagy-mediated reentry of Francisella tularensis into the endocytic compartment after cytoplasmic replication. Proc Natl Acad Sci U S A. 2006;103(39):14578–83.PubMedCentralPubMed
35.
Cullinane M, Gong L, Li X, et al. Stimulation of autophagy suppresses the intracellular survival of Burkholderia pseudomallei in mammalian cell lines. Autophagy. 2008;4(6):744–53.PubMed
36.
Gutierrez MG, Master SS, Singh SB, et al. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell. 2004;119(6):753–66.PubMed
37.
Liang XH, Kleeman LK, Jiang HH, et al. Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. J Virol. 1998;72(11):8586–96.PubMedCentralPubMed
38.
Ling YM, Shaw MH, Ayala C, et al. Vacuolar and plasma membrane stripping and autophagic elimination of Toxoplasma gondii in primed effector macrophages. J Exp Med. 2006;203(9):2063–71.PubMedCentralPubMed
39.
Liu Y, Schiff M, Czymmek K, et al. Autophagy regulates programmed cell death during the plant innate immune response. Cell. 2005;121(4):567–77.PubMed
40.
Nakagawa I, Amano A, Mizushima N, et al. Autophagy defends cells against invading group A Streptococcus. Science. 2004;306(5698):1037–40.PubMed
41.
Ogawa M, Yoshimori T, Suzuki T, et al. Escape of intracellular Shigella from autophagy. Science. 2005;307(5710):727–31.PubMed
42.
Orvedahl A, Alexander D, Talloczy Z, et al. HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe. 2007;1(1):23–35.PubMed
43.
Py BF, Lipinski MM, Yuan J. Autophagy limits Listeria monocytogenes intracellular growth in the early phase of primary infection. Autophagy. 2007;3(2):117–25.PubMed
44.
Singh SB, Davis AS, Taylor GA, Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science. 2006;313(5792):1438–41.PubMed
45.
Talloczy Z, Jiang W, Virgin HWt, et al. Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway. Proc Natl Acad Sci U S A. 2002;99(1):190–5.PubMedCentralPubMed
46.
Yano T, Mita S, Ohmori H, et al. Autophagic control of listeria through intracellular innate immune recognition in drosophila. Nat Immunol. 2008;9(8):908–16.PubMedCentralPubMed
47.
Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;451(7182):1069–75.PubMedCentralPubMed
48.
Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006;443(7113):780–6.PubMed
49.
Iwata J, Ezaki J, Komatsu M, et al. Excess peroxisomes are degraded by autophagic machinery in mammals. J Biol Chem. 2006;281(7):4035–41.PubMed
50.
Okamoto K, Kondo-Okamoto N, Ohsumi Y. Mitochondria-anchored receptor Atg32 mediates degradation of mitochondria via selective autophagy. Dev Cell. 2009;17(1):87–97.PubMed
51.
Bernales S, McDonald KL, Walter P. Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response. PLoS Biol. 2006;4(12):e423.PubMedCentralPubMed
52.
53.
54.
Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007;39(2):207–11.PubMed
55.
Massey DC, Parkes M. Genome-wide association scanning highlights two autophagy genes, ATG16L1 and IRGM, as being significantly associated with Crohn’s disease. Autophagy. 2007;3(6):649–51.PubMed
56.
Kuballa P, Huett A, Rioux JD, Daly MJ, Xavier RJ. Impaired autophagy of an intracellular pathogen induced by a Crohn’s disease associated ATG16L1 variant. PLoS One. 2008;3(10):e3391.PubMedCentralPubMed
57.
Zhang H, Massey D, Tremelling M, Parkes M. Genetics of inflammatory bowel disease: clues to pathogenesis. Br Med Bull. 2008;87:17–30.PubMed
58.
59.
Lerena C, Calligaris SD, Colombo MI. Autophagy: for better or for worse, in good times or in bad times. Curr Mol Med. 2008;8(2):92–101.PubMed
60.
Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol. 2008;9(12):1004–10.PubMedCentralPubMed
61.
Kim M, Ashida H, Ogawa M, et al. Bacterial interactions with the host epithelium. Cell Host Microbe. 2010;8(1):20–35.PubMed
62.
Huang J, Brumell JH. Autophagy in immunity against intracellular bacteria. Curr Top Microbiol Immunol. 2009;335:189–215.PubMed
63.
64.
Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol. 2010;22(2):124–31.PubMedCentralPubMed
65.
Yousefi S, Simon HU. Autophagy in cells of the blood. Biochim Biophys Acta. 2009;1793(9):1461–4.PubMed
66.
67.
Hall PA, Coates PJ, Ansari B, Hopwood D. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci. 1994;107(Pt 12):3569–77.PubMed
68.
Potten CS. The significance of spontaneous and induced apoptosis in the gastrointestinal tract of mice. Cancer Metastasis Rev. 1992;11(2):179–95.PubMed
69.
Mathan MM, Mathan VI. Morphology of rectal mucosa of patients with shigellosis. Rev Infect Dis. 1991;13(Suppl. 4):S314–8.
70.
Savidge TC, Shmakov AN, Walker-Smith JA, Phillips AD. Epithelial cell proliferation in childhood enteropathies. Gut. 1996;39(2):185–93.PubMedCentralPubMed
71.
Islam MM, Azad AK, Bardhan PK, Raqib R, Islam D. Pathology of shigellosis and its complications. Histopathology. 1994;24(1):65–71.PubMed
72.
Sachdev HP, Chadha V, Malhotra V, Verghese A, Puri RK. Rectal histopathology in endemic Shigella and Salmonella diarrhea. J Pediatr Gastroenterol Nutr. 1993;16(1):33–8.PubMed
73.
Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol. 2005;43(7):3380–9.PubMedCentralPubMed
74.
Pacelli R, Wink DA, Cook JA, et al. Nitric oxide potentiates hydrogen peroxide-induced killing of Escherichia coli. J Exp Med. 1995;182(5):1469–79.PubMed
75.
Weersma RK, van Dullemen HM, van der Steege G, et al. Review article: Inflammatory bowel disease and genetics. Aliment Pharmacol Ther. 2007;26(Suppl. 2):57–65.PubMed
76.
Wapenaar MC, Monsuur AJ, van Bodegraven AA, et al. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. Gut. 2008;57(4):463–7.PubMed
77.
Strus M, Gosiewski T, Fyderek K, et al. A role of hydrogen peroxide producing commensal bacteria present in colon of adolescents with inflammatory bowel disease in perpetuation of the inflammatory process. J Physiol Pharmacol. 2009;60(Suppl. 6):49–54.PubMed
78.
Denning TL, Takaishi H, Crowe SE, et al. Oxidative stress induces the expression of Fas and Fas ligand and apoptosis in murine intestinal epithelial cells. Free Radic Biol Med. 2002;33(12):1641–50.PubMed
79.
Kaczmarek M, Frydrychowicz M, Nowicka A, et al. Influence of pleural macrophages on proliferative activity and apoptosis regulating proteins of malignant cells. J Physiol Pharmacol. 2008;59(Suppl. 6):321–30.PubMed
80.
Kruidenier L, Kuiper I, Lamers CB, Verspaget HW. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol. 2003;201(1):28–36.PubMed
81.
Kim JM, Eckmann L, Savidge TC, et al. Apoptosis of human intestinal epithelial cells after bacterial invasion. J Clin Invest. 1998;102(10):1815–23.PubMedCentralPubMed
82.
Jain MV, Paczulla AM, Klonisch T, et al. Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development. J Cell Mol Med. 2013;17(1):12–29.PubMed
83.
Skulachev VP. Bioenergetic aspects of apoptosis, necrosis and mitoptosis. Apoptosis. 2006;11(4):473–85.PubMed
84.
Los M, Mozoluk M, Ferrari D, et al. Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol Biol Cell. 2002;13(3):978–88.PubMedCentralPubMed
85.
Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med. 1994;45:491–503.PubMed
86.
Rahman MM, Lucas AR, McFadden G. Viral TNF inhibitors as potential therapeutics. Adv Exp Med Biol. 2009;666:64–77.PubMed
87.
Chouaib S, Robinet E, Zyad A, Branellec D. Tumor necrosis factor: pleiotropic cytokine. Bull Cancer. 1992;79(10):935–49.PubMed
88.
Sidhu RS, Bollon AP. Tumor necrosis factor activities and cancer therapy–a perspective. Pharmacol Ther. 1993;57(1):79–128.PubMed
89.
Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford). 2005;44(6):714–20.
90.
Nash PT, Florin TH. Tumour necrosis factor inhibitors. Med J Aust. 2005;183(4):205–8.PubMed
91.
Zariffard MR, Novak RM, Lurain N, et al. Induction of tumor necrosis factor- alpha secretion and toll-like receptor 2 and 4 mRNA expression by genital mucosal fluids from women with bacterial vaginosis. J Infect Dis. 2005;191(11):1913–21.PubMed
92.
Wang J, Barke RA, Charboneau R, Roy S. Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection. J Immunol. 2005;174(1):426–34.PubMed
93.
Turner JD, Langley RS, Johnston KL, et al. Wolbachia endosymbiotic bacteria of Brugia malayi mediate macrophage tolerance to TLR- and CD40-specific stimuli in a MyD88/TLR2-dependent manner. J Immunol. 2006;177(2):1240–9.PubMed
94.
Corredor J, Yan F, Shen CC, et al. Tumor necrosis factor regulates intestinal epithelial cell migration by receptor-dependent mechanisms. Am J Physiol Cell Physiol. 2003;284(4):C953–61.PubMed
95.
Plevy SE, Landers CJ, Prehn J, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol. 1997; 159(12):6276–82.
96.
Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–35.
97.
Saito M, Katsuno T, Nakagawa T, et al. Intestinal epithelial cells with impaired autophagy lose their adhesive capacity in the presence of TNF-alpha. Dig Dis Sci. 2012;57(8):2022–30.PubMed
98.
Holler N, Zaru R, Micheau O, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2000;1(6):489–95.PubMed
99.
Vercammen D, Vandenabeele P, Beyaert R, Declercq W, Fiers W. Tumour necrosis factor-induced necrosis versus anti-Fas-induced apoptosis in L929 cells. Cytokine. 1997;9(11):801–8.PubMed
100.
Gunther C, Martini E, Wittkopf N, et al. Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature. 2011;477(7364):335–9.PubMedCentralPubMed
101.
Pastorelli L, De Salvo C, Mercado JR, Vecchi M, Pizarro TT. Central Role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol. 2013;4:280.PubMedCentralPubMed
102.
Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs. 2005;65(16):2253–86.PubMed
103.
Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn’s disease. Am J Gastroenterol. 2002;97(8):2000–4.PubMed
104.
Suenaert P, Bulteel V, Vermeire S, et al. Hyperresponsiveness of the mucosal barrier in Crohn’s disease is not tumor necrosis factor-dependent. Inflamm Bowel Dis. 2005;11(7):667–73.PubMed
105.
Mirpuri J, Brazil JC, Berardinelli AJ, et al. Commensal Escherichia coli reduces epithelial apoptosis through IFN-alphaA-mediated induction of guanylate binding protein-1 in human and murine models of developing intestine. J Immunol. 2010;184(12):7186–95.PubMedCentralPubMed
106.
Ivanov, II, Frutos Rde L, Manel N, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe. 2008;4(4):337–49.PubMedCentralPubMed
107.
Onizawa M, Nagaishi T, Kanai T, et al. Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2009;296(4):G850–9.PubMed
108.
Kanai T, Totsuka T, Uraushihara K, et al. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol. 2003;171(8):4156–63.PubMed
109.
MacDonald TT, Monteleone G, Pender SL. Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol. 2000;51(1):2–9.PubMed
110.
Totsuka T, Kanai T, Iiyama R, et al. Ameliorating effect of anti-inducible costimulator monoclonal antibody in a murine model of chronic colitis. Gastroenterology. 2003;124(2):410–21.PubMed
111.
Lapaquette P, Brest P, Hofman P, Darfeuille-Michaud A. Etiology of Crohn’s disease: many roads lead to autophagy. J Mol Med (Berl). 2012;90(9):987–96.
112.
Cadwell K, Patel KK, Maloney NS, et al. Virus-plus-susceptibility gene interaction determines Crohn’s disease gene Atg16L1 phenotypes in intestine. Cell. 2010;141(7):1135–45.PubMedCentralPubMed
113.
Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet. 1991;338(8770):771–4.PubMed
114.
Man SM, Kaakoush NO, Mitchell HM. The role of bacteria and pattern-recognition receptors in Crohn’s disease. Nat Rev Gastroenterol Hepatol. 2011;8(3):152–68.PubMed
115.
Pagnini C, Cominelli F. Probiotics in experimental and human inflammatory bowel disease: discussion points. Dig Liver Dis. 2006;38(Suppl. 2):S270–3.
116.
Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis. 2008;14(11):1585–96.PubMed
117.
Bai AP, Ouyang Q. Probiotics and inflammatory bowel diseases. Postgrad med J. 2006;82(968):376–82.
118.
Bernet MF, Brassart D, Neeser JR, Servin AL. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut. 1994;35(4):483–9.PubMedCentralPubMed
119.
Schultz M, Lindstrom AL. Rationale for probiotic treatment strategies in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2008;2(3):337–55.PubMed
120.
Maddika S, Ande SR, Panigrahi S, et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat. 2007;10(1–2):13–29.PubMed
121.
Chaabane W, User SD, El-Gazzah M, et al. Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer. Arch Immunol Ther Exp (Warsz). 2013;61(1):43–58.
122.
Stroh C, Cassens U, Samraj A, et al. The role of caspases in cryoinjury: caspase inhibition strongly improves the recovery of cryopreserved hematopoietic and other cells. FASEB J. 2002;16(12):1651–3.PubMed
123.
Alavian SM, Ande SR, Coombs KM, et al. Virus-triggered autophagy in viral hepatitis—possible novel strategies for drug development. J Viral Hepat. 2011;18(12):821–30.PubMed
124.
Panigrahi S, Stetefeld J, Jangamreddy JR, et al. Modeling of molecular interaction between apoptin, BCR-Abl and CrkL–an alternative approach to conventional rational drug design. PLoS One. 2012;7(1):e28395.
Metadaten
Titel
Biological pathways involved in the development of inflammatory bowel disease
verfasst von
Dr. Mateja Zemljic, PhD
Prof. Bozena Pejkovic
Prof. Ivan Krajnc
Docent Saska Lipovsek
Publikationsdatum
01.10.2014
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 19-20/2014
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-014-0592-7

Weitere Artikel der Ausgabe 19-20/2014

Prediction of cancer incidence in Tyrol/Austria for year of diagnosis 2020

  • original article

Patient-specific evaluation of knee disorders in clinical practice

  • original article

Daytime sleepiness in patients with obstructive sleep apnea and severe obesity: prevalence, predictors, and therapy

  • original article

ÖGIM Flip

  • mitteilungen der gesellschaft

The relationship between mean platelet volume and pelvic inflammatory disease

  • letter to the editor

Researcher of the Month

  • MUW researcher of the month